Señales en vivo de GRCL | Maximiza tus Ganancias con Getagraph.com

COMPRAR 113510 min ago

@ CNY10.28

Emitido: 14 feb 2024 @ 15:48

Retorno: -0.29%

Señal anterior: feb 14 - 13:13

Señal anterior: Vender

Retorno: -0.48 %

Live Chart Being Loaded With Signals

Commentary (21 feb 2024 @ 16:00):

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...

Stats
Volumen de hoy	6.37M
Volumen promedio	1.46M
Capitalización de mercado	989.87M
EPS	CNY0 ( 2024-03-11 )
Próxima fecha de ganancias	( CNY0 ) 2024-05-13
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-10.57
ATR14	CNY0.215 (2.10%)

Volumen Correlación

Largo: 0.31 (neutral)

Corto: 0.24 (neutral)

Signal:(68.183) Neutral

Gracell Biotechnologies Correlación

10 Correlaciones Más Positivas
NTRA	0.988
CRAI	0.983
RNA	0.976
HARP	0.976
PNTG	0.975
XLRN	0.974
ATRS	0.972
GXII	0.971
SFM	0.971
ARYD	0.97

10 Correlaciones Más Negativas
LPSN	-0.974
NARI	-0.971
BMBL	-0.97
VORB	-0.968
PEAR	-0.963
QNRX	-0.958
AMPH	-0.958
AKAN	-0.957
CNXC	-0.956
DMTK	-0.955

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gracell Biotechnologies Correlación - Moneda/Commodity

0.54
( weak )

0.89
( strong )

-0.03
( neutral )

0.35
( neutral )

0.23
( neutral )

-0.79
( moderate negative )

Gracell Biotechnologies Finanzas

Annual	2022
Ingresos:	CNY0
Beneficio Bruto:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2022
Ingresos:	CNY0
Beneficio Bruto:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2021
Ingresos:	CNY366 000
Beneficio Bruto:	CNY0.00 (0.00 %)
EPS:	CNY-4.31

FY	2020
Ingresos:	CNY0.00
Beneficio Bruto:	CNY0.00 (0.00 %)
EPS:	CNY-13.85

Financial Reports:

No articles found.

Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.